# Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial

> **Open Intelligence Dossier** · First detected: 2026-09-25 20:00 UTC · Category: Health

## Executive Summary
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial" is generating significant coverage in the Health category, with 4 articles from 4 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Medscape, medicalxpress.com, Cardiovascular Business and Oxford Academic. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Medscape | Semaglutide Found to Benefit Frail Patients | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbEdQUHpNZW5ZZmlPNWZEZ0RTb3Y3R3lVMlhvTElMVVBXWXpEeko3VWZmRTd2cHB6RHAzcUR0RldDSDJBN1FNai1zdHEtS1B5WlZEMk9Ca19LUV9hRjJOcnBGeXFIVUV4SHA5Ync1c243Z2JOYUIzbENPQlFjZXB6TVlHZGg5TVZKeUJaQzJUOGhHZGZOeC1uYVppci1LRm4yaDl5a05CajdOZw?oc=5) |
| medicalxpress.com | Weight loss alone does not explain lower heart disease risk for those on semaglutide | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxNLXZBclZNRVZXQWR1U3BfbENxNGxCRHNCREx4X0tvbThTQkozeVVHcHk1aXVkazJycm1YY29kdTZ4bFlaSEZCMEx5cW1NRHg1aUlic2kzMFZUcFlrMFllVnpUZ0xpem51VUoxUGwwUGFXTlhNRUNDamtWY0x2UjdGY1YyM2t0eE1S?oc=5) |
| Cardiovascular Business | Semaglutide is improving the heart health of millions—but how? Experts are stumped | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxQY18tdWdQMWY0bi1QdVdEZENrb3VfR0J0NVlYTm9SbzlVcDJ2QndBbzRDQnR2T2pTcjNyRVhJQzV1N0pMVjdSNlRiQVdCUWFWdlZTeHRxbHdkZnpiQ2Nad3RWdzJrc3RBM1F6Z09EYlRYMU1LdUYzeHIyUXpmM3NJVmdmcTVZQWlBenlsNmVwU1A5YzNQOHpnVi1mUVNpZjlRWVc1U2Nn?oc=5) |
| Oxford Academic | Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxPT25VdS15dXd6SWVtZDJYdkZSeEtWS0NfZE1fV2xmQ0FyNVBqUktxcE9tLUxWQWQzaXpRLXE2cG4yRWtqclBKZXdRNVNURFAwUmkyM2g3Q0FnV3ZnbV8za0tvVU5HZWh2Q0RwVThYbjd4cS1kNnFXMy1iNkhSLU9oRkRNdXFXdTBFOHpUejlmbWp1Zw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-25/semaglutide-and-cardiovascular-risk-reduction-a-mediation-analysis-of-the*